<SubstanceDefinition xmlns="http://hl7.org/fhir"><id value="mipomersen"/><identifier><system value="http://example.europa.eu/fhir/SMSId"/><value value="MIPO78654S"/></identifier><status><coding><system value="http://hl7.org/fhir/publication-status"/><code value="active"/></coding></status><classification><coding><system value="http://example.europa.eu/fhir/SubstanceType"/><code value="nucleic-acid"/><display value="Nucleic Acid"/></coding></classification><domain><coding><system value="http://example.europa.eu/fhir/Domain"/><code value="human"/><display value="Human use"/></coding></domain><description value="Mipomersen sodium — a synthetic second-generation 2'-methoxyethyl antisense oligonucleotide that inhibits the molecular target apolipoprotein B-100 (APOB-100). 20-mer phosphorothioate-linked sequence with 2'-MOE wing chemistry."/><code><code><coding><system value="http://example.europa.eu/fhir/Substance"/><code value="MIPO78654S"/></coding></code></code><name><name value="Mipomersen Sodium"/><preferred value="true"/><language><coding><system value="urn:ietf:bcp:47"/><code value="en"/><display value="English"/></coding></language><official><authority><coding><system value="http://hl7.org/fhir/substance-name-authority"/><code value="INN"/><display value="INN"/></coding></authority><status><coding><system value="http://hl7.org/fhir/publication-status"/><code value="active"/><display value="Active"/></coding></status></official></name><nucleicAcid><sequenceType><coding><system value="http://hl7.org/fhir/substance-sequence-type"/><code value="complete"/><display value="Complete"/></coding></sequenceType><numberOfSubunits value="1"/><oligoNucleotideType><coding><system value="http://hl7.org/fhir/oligo-nucleotide-type"/><code value="antisense"/><display value="Antisense oligonucleotide"/></coding></oligoNucleotideType><subunit><subunit value="1"/><sequence value="GCCUCAGTCTGCTTCGCACC"/><length value="20"/><fivePrime><coding><system value="http://hl7.org/fhir/nucleotide-terminus"/><code value="G"/><display value="Guanosine"/></coding></fivePrime><threePrime><coding><system value="http://hl7.org/fhir/nucleotide-terminus"/><code value="C"/><display value="Cytidine"/></coding></threePrime><linkage><connectivity/><substance><concept><coding><system value="http://example.europa.eu/fhir/LinkageSubstance"/><code value="phosphorothioate"/><display value="Phosphorothioate linkage"/></coding></concept></substance><residueSite value="1-19"/></linkage><sugar><substance><concept><coding><system value="http://example.europa.eu/fhir/SugarSubstance"/><code value="2-MOE"/><display value="2'-O-(2-methoxyethyl) ribose"/></coding></concept></substance><residueSite value="1-5,16-20"/></sugar><sugar><substance><concept><coding><system value="http://example.europa.eu/fhir/SugarSubstance"/><code value="deoxyribose"/><display value="2'-deoxyribose"/></coding></concept></substance><residueSite value="6-15"/></sugar></subunit><gene><sequenceOrigin><coding><system value="http://hl7.org/fhir/gene-sequence-origin"/><code value="human"/><display value="Human"/></coding></sequenceOrigin><gene><concept><coding><system value="http://www.genenames.org"/><code value="APOB"/><display value="apolipoprotein B"/></coding></concept></gene></gene></nucleicAcid><relationship><substanceDefinitionCodeableConcept><coding><system value="https://www.uniprot.org"/><code value="P04114"/><display value="apolipoprotein B-100"/></coding></substanceDefinitionCodeableConcept><type><coding><system value="http://hl7.org/fhir/substance-relationship-type"/><code value="TherapeuticTarget"/><display value="Therapeutic target"/></coding></type><interaction><coding><system value="http://hl7.org/fhir/substance-interaction-type"/><code value="inhibition"/><display value="Inhibition"/></coding></interaction></relationship></SubstanceDefinition>